SEAGEN INC.
BOTHELL, WA

Based in Bothell, Washington and known for its cutting-edge work in oncology biotechnology, Seattle Genetics Inc. has been revolutionizing cancer treatment since its incorporation on January 24, 2011. Renowned for its innovative antibody-drug conjugate (ADC) technology, the company aims to turn advanced therapies into real-world cancer solutions. Their flagship product, ADCETRIS® (brentuximab vedotin), stands out as the first of its kind in ADCs approved globally in 70 countries. Primarily used for relapsed classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma, it also serves additional roles in the U.S., offering new hope to patients battling these conditions. A testament to their commitment, Seattle Genetics has teamed up with industry giants such as Astellas Pharma Inc., Genentech (Roche Group), AbbVie, GlaxoSmithKline, and Pfizer. As a result of these partnerships, the company successfully generated over $375 million through strategic licensing agreements. The team's drive comes from their core values: fostering scientific innovation, maintaining integrity, encouraging teamwork, and upholding rigorous research practices. With leaders like John A. Orwin (CEO since 2013 before moving to Relypsa), COO Alpna Seth who joined in July 2017 after her tenure at Biogen, Inc., alongside Frances Sewell, Shehzad Siddiqui, and Susan Grant, Seattle Genetics is continually pushing the frontiers of oncology care. At its heart, Seattle Genetics is home to a vibrant culture that prizes excellence. Leveraging innovation and strategic partnerships, it aims to lead growth in the biotech landscape. You can find their headquarters at 21823 30th Drive SE, Bothell, WA 98021 or reach them via various contact numbers like 425-527-4000. For those interested in learning more or staying updated about their innovations and community impact, visit Seattle Genetics' official website: [seattlegenetics.com](http://seattlegenetics.com).